Patritumab: Ph II ongoing

Daiichi said patritumab will be evaluated in the ongoing Phase II I-SPY 2 trial, which is designed to rapidly and inexpensively test

Read the full 221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE